Survodutide
Every GLP-1 the FDA has approved, and the active ingredient inside each one.
What is Survodutide?
Boehringer Ingelheim and Zealand Pharma are developing this one, an investigational agonist hitting both the GLP-1 and glucagon receptors.
Phase 2 reported up to 19% weight loss at 46 weeks and the phase 3 SYNCHRONIZE program is enrolled. Not approved.
GLP-1 pipeline: survodutide, MariTide, ecnoglutide →
GLP Watchdog writes these definitions from FDA labels and peer-reviewed PubMed literature.
Where Survodutide comes up on this site
On GLP Watchdog, Survodutide comes up in 1 research article and 2 FDA warning letters. Browse the FDA warning letters.
Research that discusses it
Connected terms
Other terms under Drugs and brands
Where the evidence lives
- GLP-1 pipeline: survodutide, MariTide, ecnoglutide
- The full GLP-1 glossary (149 terms, 8 categories)
- Research articles — written from primary sources
- Tools and calculators
- Compare GLP-1 telehealth providers